BP, Unlilever among Investors Pouring $49M into ZeaChem, Chromatin, Agradis
by Jim Lane (Biofuels Digest) …There’s a rumor going around the biofuels and biomaterials business that today represents one of the most difficult periods to raise capital. Apparently, the rumors did not reach ZeaChem, Chromatin or Synthetic Genomics, which this week made separate announcement that they had raised $49 million in fresh venture rounds. Chromatin raised $10 million in a series D round, ZeaChem raised $19 million in a series C round, and Synthetic Genomics raised $20 million in a series A round for its new spin-off Agradis.
Among the investors who also apparently did not receive the “don’t invest now” memorandum were Unilever, BP, Firelake Capital, Globespan Capital Partners, Mohr Davidow Ventures, PrairieGold Venture Partners and Spring Ventures, Quantitative Investment Holdings, the Malaysian Life Sciences Capital Fund, Illinois Ventures, Plenus and Draper Fisher Jurvetson, among others. READ MORE and MORE (Gigaom) and MORE (MIT Technology Review) and MORE (Biorefining Magazine)
